Why Synthetic Data is the Antidote to Clinical Trials
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis.
To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis.
"We spend a lot of time focused on building the experiences that we think are the future of healthcare, and we don't spend a heck of a lot of time worrying about what other people are doing," declares Dan Caron, founder and CEO of Health Universe. Here's a Q&A with the leader of the Kleiner Perkins-backed company.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
The application of AI technology is part of a carefully orchestrated effort dependent on human intelligence, and the collaboration of physicians, disease-specific specialists, nurses, data scientists, and technologists. Done right, these efforts can lead to profound benefits, and offer a promising future for clinical research and patient care.
Watershed Health closed a $13.6 million funding round this week. The New Orleans-based company seeks to improve care coordination by connecting providers of all types across the healthcare system.
In order to understand the current state of the healthcare system it is essential to have comprehensive sources of real-world and integrated data linked with data from across the healthcare ecosystem.
In clinical trials, pharmaceutical companies are seeking to optimize operations and improve efficiency by automating and enhancing processes through Artificial Intelligence (AI) and Machine Learning (ML). One area where this can reap tangible benefits across clinical trials is in data processing. A typical clinical trial generates over 13,000 documents in various formats (text, voice, video, […]
How to turn analytics into actual policy outcomes.
During my 25 years in oncologic drug discovery, development and commercialization, I have seen how economic cycles can skew priorities and slow progress – but we cannot let that happen.
To maximize the digital clinical trial opportunity, it is imperative to establish a solid foundation of data collection and management best practices and capitalize on the advancements in data management technologies.
For a long time, doctors’ offices, large or small, operated under a seeming contradiction; even as modern medicine pushed the frontiers of innovation, providing new treatments and sometimes cures for devastating diseases, so much of our healthcare system remained stuck in the pre-digital past. The most obvious example is one that many of us have […]
Artificial intelligence can help drug study teams solve operational, scientific and ethical challenges. For example, AI can be used to flag real-time trends emerging in drug trials that might otherwise not be obvious until the end of a study when all the data is analyzed.
AI’s ability to quickly scan and synthesize huge volumes of information is being adopted for numerous healthcare initiatives, including use in pharmaceutical drug discovery and development.
The science of using sensor data to define, measure, and create mathematical models of disease can lead to better outcomes—and huge benefits—for everyone in healthcare and life sciences.